Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Next Previous
Trial Profile

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics

Most Recent Events

  • 17 Feb 2023 Results of post-hoc analysis of 2 studies (NCT02089256 and NCT03160261) assessing effect of a short-acting and a long-acting GLP-1 RA on GH secretion, published in the Diabetes Therapy.
  • 31 Mar 2017 Results published in the Journal of Clinical Endocrinology and Metabolism
  • 31 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top